NCT05598177CompletedPhase 4
Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass
Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion : a Randomized, Double-blind Clinical Trial
Source: ClinicalTrials.gov · Last updated 21 Mar 2024
Brief summary (registry, in English)
About 200000 cardiac operations are performed in China every year. Cardiopulmonary bypass is the basic strategy of open-heart surgery, which may lead to myocardial ischemia-reperfusion injury and low cardiac output syndrome. It will inevitably affect the patient's postoperative recovery. A number of studies have shown that dexmedetomidine, as an auxiliary sedative, has the effects of inhibiting stress response, antiarrhythmia and cardiac protection.Dexmedetomidine has been widely used in anesthesia in cardiac surgery. However, at present, few clinical studies pay attention to its mechanism. In this study, dexmedetomidine will be used in cardiac surgery with cardiopulmonary bypass to explore the mechanism of cardiac ischemia-reperfusion injury and the protective effect of dexmedetomidine.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- First submitted
- 25 Oct 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 30 May 2023
- Lead sponsor
- Affiliated Hospital of Nantong University
- NCT number
- NCT05598177
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 64
- From 1 Sept 2022 to the primary completion date, 30 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Preoperative diagnosis of heart failure 、gradeⅡ-Ⅲ heart block and diabetes
- Severe heart, lung, liver and kidney insufficiency
- Used to have immunosuppressive therapies such as radiotherapy, chemotherapy and glucocorticoid, or have immune system diseases
Other
- LEVF\<40%
- Severe coagulation dysfunction
- Perioperative allogeneic blood transfusion
Who the study is looking for
- Aged 18-70 years
- American Society of Anesthesiologists(ASA) physical status of I-Ⅳ
- BMI: 18.5-28 kg/m2
- Type of operation: elective open-heart surgery with cardiopulmonary bypass
- The patient and/or family members have signed the informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Affiliated Hospital Nantong University Coordinator of this site? Confirm its status | Nantong | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.